TD Cowen Reiterates Buy Rating on MaxCyte Inc. (MXCT) Sep 24, 2024 08:38AM
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences Feb 9, 2024 08:05AM
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences Feb 1, 2023 04:05PM
MaxCyte Inc. (MXCT) Named Best SMIDcap Idea at Cowen Jun 23, 2022 06:56AM
MaxCyte to Participate in Upcoming Investor Conferences Feb 14, 2022 08:00AM


Aug 24, 2021 06:35AM Cowen Starts MaxCyte Inc. (MXCT) at Outperform
Jul 30, 2021 12:19PM IPO for Cell-Engineering Firm MaxCyte (MXCT) Opens 31% Higher
Jul 30, 2021 05:26AM MaxCyte, Inc. (MXCT) Prices Upsized 13.5M Share Nasdaq IPO at $13/sh
Jul 29, 2021 10:42PM MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
Jul 26, 2021 07:50AM MaxCyte, Inc (MXCT) Announced 12M Share IPO at $11.50-$13.50
Jul 26, 2021 07:49AM MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market
Jul 12, 2021 05:20AM MaxCyte, Inc (MXCT) Files up to $100M IPO
Jul 12, 2021 02:00AM MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing